NCT04132960
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: HER2-low
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients with HER2+ tumors must have been treated & have progressed on trastuzumab (Herceptin) and on TDM-1 (Kadcyla); Patients with HER2-negative & HR+ tumors must be resistant to endocrine therapy & CDK4/6 inhibitors, & must have been treated with capecitabine (Xeloda)
Exclusions: Patients with spinal cord compression or active central nervous system (CNS) metastases, defined as untreated and symptomatic, or requiring therapy – see trial for details; Patients with bone metastatic disease only; Patients previously treated with a topoisomerase 1 inhibitor (e.g. Etirinotecan, Irinotecan, Enhertu)
https://ClinicalTrials.gov/show/NCT04132960